Treatment of pulmonary arterial hypertension (PAH)

Kurzbeschreibung:
A new therapy for pulmonary arterial hypertension (PAH) is to be developed.

Kontakt:
TransMIT GmbH
Kerkrader Str. 3
35394 Gießen
Telefon: +49 (6 41) 9 43 64 - 0
E-Mail: patente@transmit.de

orphan disease, small-molecule compounds, pulmonary arterial hypertension (PAH), benzimidazole derivates, epigenetic modulation-based therapy